Propafenone is a Class Ic drug with targets INa, IKr and IKur currents as well as beta receptors and alpha receptors [1,2].

It can cause PR interval prolongation, QRS widening and an increase in the defibrillation threshold (DFT).

Propafenone has a half life of 2- 10 hours, suggesting an eight hourly dosage.

It is useful in the treatment of ventricular tachycardia (VT) and frequent premature ventricular complexes (PVC), in the absence of structural heart disease.

Like flecainide, it can cause drug-induced Brugada syndrome and may worsen heart failure and atrioventricular (AV) block.


  1. Ming Lei, Lin Wu, Derek A Terrar, Christopher L-H Huang. Modernized Classification of Cardiac Antiarrhythmic Drugs. Circulation. 2018 Oct 23;138(17):1879-1896.
  2. Sana M Al-Khatib, William G Stevenson, Michael J Ackerman, William J Bryant, David J Callans, Anne B Curtis, Barbara J Deal, Timm Dickfeld, Michael E Field, Gregg C Fonarow, Anne M Gillis, Christopher B Granger, Stephen C Hammill, Mark A Hlatky, José A Joglar, G Neal Kay, Daniel D Matlock, Robert J Myerburg, Richard L Page. 2017 AHA/ACC/HRS Guideline for Management of Patients With Ventricular Arrhythmias and the Prevention of Sudden Cardiac Death: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines and the Heart Rhythm Society. J Am Coll Cardiol. 2018 Oct 2;72(14):e91-e220.